1.
Ter Arkh
; 91(2): 109-117, 2019 Mar 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31094181
RESUMO
The article presents an update of the role of non-alcoholic fatty liver disease (NAFLD) in cardiometabolic diseases and events: arterial hypertension and components of the metabolic syndrome. A review of NAFLD modern pharmacotherapy has been conducted. Particular attention is paid to the place of ursodeoxycholic acid in the complex treatment of NAFLD.